Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX1 | Q96LB2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RBP4 | P02753 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.41 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469544 | 0.81 | NPC1 (0.53) | ALDH1A1SCN9ASCN5AAURKATPX2 | |
| SCHEMBL27021671 | 0.79 | SCN9A (0.39) | MRGPRX1ALDH1A1LMNASCN9ASCN5A | |
| SCHEMBL13129173 | 0.79 | MYC (0.54) | ALDH1A1LMNAKCNK3KCNK9 | |
| SCHEMBL16759704 | 0.78 | HPGD (0.58) | ALDH1A1LMNARBP4SCN9ASCN5A | |
| SCHEMBL18798787 | 0.75 | KDM4E (0.64) | — | |
| SCHEMBL15714572 | 0.74 | MYC (0.68) | MRGPRX1RBP4SCN9ASCN5AAURKA | |
| SCHEMBL15614408 | 0.74 | NPC1 (0.55) | ALDH1A1LMNA | |
| SCHEMBL16361274 | 0.74 | SCN9A (0.49) | ALDH1A1LMNASCN9ASCN5A | |
| SCHEMBL3808268 | 0.74 | HDAC3 (0.50) | LMNASCN9ASCN5A | |
| SCHEMBL2737229 | 0.73 | L3MBTL1 (0.67) | MRGPRX1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028098-B2 | 4-phenylpiperidines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-06-08 | — | — | US | disclosed |
| US-10273243-B2 | 4-phenylpiperidines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-04-30 | — | — | US | disclosed |
| US-20190031681-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-01-31 | — | — | US | disclosed |
| US-9944644-B2 | Octahydropyrrolopyrroles their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-04-17 | — | — | US | disclosed |
| US-9938291-B2 | N-alkyl-2-phenoxyethanamines, their preparation and use | THE TRUSTESS OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-04-10 | — | — | US | disclosed |
| US-9637450-B2 | Octahydrocyclopentapyrroles, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273243-B2 | 4-phenylpiperidines, their preparation and use | HTR3C, HRH4, CYP4F3 | MRGPRX1 1117/4885ALDH1A1 2473/4885LMNA 4665/4885 |
| US-11028098-B2 | 4-phenylpiperidines, their preparation and use | HTR3C, HRH4, CYP4F3 | MRGPRX1 1188/4885ALDH1A1 2360/4885LMNA 4617/4885 |
| US-20190031681-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | HTR3C, HRH4, CYP4F3 | MRGPRX1 1188/4885ALDH1A1 2360/4885LMNA 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.